Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced that it is
offering to sell up to 4,000,000 shares of its common stock in an
underwritten public offering. Jefferies & Company, Inc. is acting as
sole book-running manager in the offering. The co-manager in the
offering is Oppenheimer & Co. Inc. Somaxon expects to grant the
underwriters an option to purchase up to an additional 600,000 shares of
common stock to cover overallotments of shares, if any. The offering is
subject to market conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual size
or terms of the offering.
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals